Ebola virus - a still unfamiliar opponent.
More details
Hide details
Koło Naukowe, Katedra i Klinika Chorób Wewnętrznych, Uniwersytet Medyczny w Lublinie
Zakład Wirusologii, Uniwersytet Medyczny w Lublinie
Katedra i Klinika Chorób Wewnętrznych, Uniwersytet Medyczny w Lublinie
Med Og Nauk Zdr. 2012;18(4):379–382
The Ebola virus is classified to the Filoviridae genus. The mortality rate of haemorrhagic fever fluctuates between 50%-90%. There are 5 types of this pathogen, named according to place of prevalence – Ebola-Sudan (SEBOV), Ebola-Zaire (ZEBOV), Ebola-Cote d›Ivore (CIEBOV), Ebola-Reston (REBOV) and Ebola-Bundibugyo (BEV). Objective: To draw the attention of the public to the problem of Ebolavirus infection, and to review the prophylactic methods used. Ebola virus can be transmitted by contact with the conjunctiva, musoca of the larynx or small skin lesions. The term of incubation lasts 2-21 days. The first symptoms: fever with chills and pains in muscles and joints, can be misleading. Hence, influenza is often confused with haemorrhagic fever. The leading cause of death is Multiorgan Dysfunction Syndrome (MODS), which consists of hypotensia, DIC and focal necrosis. There is still no etiotropic treatment for haemorrhagic fever. The vaccine is still the object of survey and clinical trials. In the future, a plasmid vaccine or vaccine with attenuated virus might be used. Inoculation with vaccines containing VIZV or adenovirus are also a possibility. Because of the non-existence of etiotropic treatment and methods of specific immunization, Ebolavirus infection still poses a threat for humans. Non-specific prophylaxis, such as HEPA masks, gloves and aprons are the only way to avoid transmission of the disease. Key words: Ebola virus, Ebola haemorrhagic fever, SEBOV, ZEBOV
Baron RC, McCormick JB, Zubeir OA. Ebola virus disease in southern Sudan:hospital dissemination and intrafamiliar spread. Bull World Human Organ. 1983; 63(6): 997-1003.
Łuczkiewicz M, Flaga MJ. Gorączka krwotoczna Ebola. Immunologiczne i molekularne mechanizmy patogenezy, diagnostyka, eksperymentalne metody leczenia i uodparniania. Post Mikrobiol. 2007; 46(3): 189-202.
Heymann DL, Weisfeld JS, Webb PA, et al. Ebola hemorrhagic fever: Tandala, Zaire,1977-1978. J Infect Dis. 1980; 142(3); 372-376.
Olson PE, Hames CS, Benenson AS, GEnovese EN. The Thucydides syndrome: Ebola déjà vu? (or Ebola reemergent?) Emerg Infect Dis. 1996; 2(2): 155-156.
Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech. 2009; 2(1-2): 12-17.
Chomiczewski K. Patogeny zwierzęce jako broń biologiczna. Przegl Epidemiol. 2003; 57: 355-361.
Przypadki i epidemie gorączki krwotocznej wywołanej wirusem Ebola. (dostęp: 08.09.2012 r.).
Feldmann H. Are we any closer to combating Ebola infections? Lancet 2010; 375(9729): 1850-1852.
Meldunki epidemiologiczne Państwowy Zakład Higieny http://www. (dostęp: 08.09.2012 r).
Zieliński A, Rosińska M, Gut W. Gorączki krwotoczne – epidemiologia i klinika. Przegl Epidemiol. 2003; 57: 636-54.
Global alert and response. World Health Organization http://www.who. int/csr/don/archive/disease/ebola_haemorrhagic_fever/en/ (dostęp: 08.09.2012 r.).
Pigott DC. Hemorrhagic fever viruses. Crit Care Clin. 2005; 21: 765- 783,vii.
Encyklopedia Britannica (dostęp: 13.09.2012 r.).
Feldmann H, Geisbert TW. Ebola hemorrhagic fever. Lancet 2011; 377(9768): 849-862.
Shi W, Huang Y, Sutton-Smith M, Tissot B, Panico M, Morris HR, et al. A filovirus-unique region of Ebola virus nucleoprotein confers aberrant migration and mediates its incorporation into virions. J Virol. 2008; 82(13): 6190-9.
Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, Klenk HD, et al. The Ebola virus VP35 protein functions as type I IFN antagonist. Proc Natl Acad Sci. USA 2000; 97(22): 12289-94.
Silva LP, Vanzile M, Bavari S, Javad Aman JM, Schriemer DC. Assembly of Ebola Virus Matrix Protein VP40 is regulated by latch-like properties of N and C terminal tails. PLoS One. 2012; 7(7): e.39978.
Sinu PJ, Wang T, Steffen S, Longhi S, Schmaljohn CS, Jonsson CB. Ebola virus VP30 is an RNA binding protein. J Virol. 2007; 81(17): 8967-8976.
Basler CF, Amarasinghe GK. Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res. 2009; 29(9): 511-520.
Gonzalez JP, Pourrut X, Leroy E. Ebolavirus and other filoviruses. Curr Top Microbiol Immunol. 2007; 315: 363-87.
Voelker R. Surviving Ebola. JAMA 1999; 281: 18.
Jaax NK. Davis KJ, Geisbert TJ, Vogel P, Jaax GP, Topper M, Jarhling PB. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med. 1996; 120(2): 140-155.
Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: implications for vaccines and therapies. J Virol. 2003; 77(18): 9733-9737.
Gołąb J, Jakóbisiak M. Fagocytoza i mechanizmy cytotoksyczności komórek żernych. W: Gołąb J, Jakóbisiak M, Lasek W, Stokłosa T, Immunologia; Wyd. 6 Warszawa: PWN;2007:107.
Wietlicka I, Korzeniowska K, Jabłecka A. Neopteryna. Farm WSP 2008; 1: 241-247.
Mehedi M, Groseth A, Feldmann H, Ebihara H. Clinical aspects of Marburg hemorrhagic fever. Future Virol. 2011; 6(9): 1091-1106.
Płusa T. Nowe trendy diagnostyki i terapii w sytuacjach zagrożenia bioterroryzmem. Przew Lek. 2008; 1: 247-249.
Gear JH, Ryan J, Rossouw E. A consideration of the diagnosis of dange¬rous infections fevers in South Africa. SAMJ 1978; 53(7): 235-7.
Grolla A, Lucht A, Dick D, Strong JE, Feldmann H. Laboratory diag¬nosis of Ebola and Marburg hemorrhagic fever. Bull Soc Pathol Exot. 2005; 98(3): 205-9.
Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of Congo: clinical observation in 103 patients. J Infect Dis. 1999; 179 Suppl: sS-7.
Ndambi R, Akamituna P, Bonnet MJ, Tukadila AM, Muyembe-Tamfum JJ, Colebunders R. Epidemiologic and clinical aspects of the Ebola virus epidemic in Mosango, Democratic Republic of Congo, 1995. J Infect Dis. 1999; 179 Suppl: S8-10.
Mupapa K, Mukundu W, Bwaka MA, Kipasa M, De Roo A, Kuvula K, et al. Ebola hemorrhagic fever and pregnancy. J Infect Dis. 1999; 179 Suppl: S11-12.
Richards GA, Murphy S, Jobson R, Mer M, Zinman C, Taylor R, et al. Unexpected Ebola virus in a tertiary setting: clinical and epidemiologic aspects. Crit Care Med. 2000; 28(1): 240-4.
Simon K. Współczesne zagrożenia epidemiologiczne w chorobach zakaźnych – postępy diagnostyczne i terapeutyczne. Przew Lek. 2007; 2: 210-215.
Barrientos LG, O’Keefe BR, Bray M, Sanchez A, Gronenborn AM, Boyd MR. Cyanovirin-N binds to the viral surface glycoprotein, GP 1,2 and inhibits infectivity of Ebola. Antiviral Res. 2003; 58(1): 47-56.
Zeitlin L, Pettitt J, Scully C, Bohorova N, Kim D, Pauly M, et al. En¬hanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci. USA 2011; 108(51): 20690-20694.
de Witt E, Feldmann H, Munster VJ, Tackling with Ebola: new insights into prophylactic and therapeutic intervention strategies. Genome Med. 2011; 3(1): 5.
Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol. 2011; 85(20): 10605-16.
Falzarano D, Geisbert TW, Feldmann H. Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines. 2011; 10(1): 63-77.
Wilson JA, Bray M, Bakken R, Hart MK. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 2001; 286(2): 384-90.